Regend Therapeutics Raises 350 million to Accelerate Pioneering Stem Cell Treatments
Published: 19 Feb 2026
Author: Precedence Research
Chinese regenerative medicine company Regend Therapeutics has secured 350 million in a Series C financing round to fast-track the development of its innovative cell therapies. A mix of new and returning investors participated in the round including Fir Brook Capital and Tasly Capital as well as Yuze Capital Hefei high tech investment hongtai fund hefei industrial investment and Gongquingcheng Fuhui. Late-stage clinical trials will advance manufacturing capabilities, will be strengthened, and the company's larger commercialization strategy in China and international markets will be supported with the new funding.
Founded in 2015, Regend Therapeutics focuses on using progenitor and stem cell technologies to regenerate damaged organs rather than simply managing disease symptoms. One of its main initiatives, REGEND001, aims to treat long-term lung conditions like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The treatment involves taking basal stem cells out of the patient's airway, growing them in a lab, and then reintroducing them into the lungs using a minimally invasive technique. Meaningful improvements in lung function and patient quality of life have been observed in early clinical results, indicating that the treatment may aid in lung structure restoration. To confirm its efficacy and safety, the company plans to start Phase 3 clinical trials in China in 2026.
Regend is developing a program called REGEND003 that targets chronic kidney disease, specifically diabetic kidney disease (DKD), in addition to its lung therapy. This therapy eliminates the need for surgery by non-invasively isolating progenitor cells from a patient's urine, in contrast to conventional methods. Early results from the program's entry into Phase 1 clinical trials suggest that kidney tissue may regenerate and that renal function indicators may improve. The company's goal to broaden the use of regenerative medicine in various organ systems is demonstrated by these developments.
Notably, REGEND001 has already been made available in China's Boao Lecheng Pilot Zone, a unique medical pilot program that provides early access to cutting-edge treatments. This deployment facilitates commercialization planning and offers practical clinical experience. Regend Therapeutics hopes to strengthen its global positioning in the quickly changing field of regenerative medicine, increase production capacity, and expedite its clinical pipeline with the recently raised funds. Growing investor confidence in the potential of stem cell-based therapies to revolutionize the treatment of degenerative and chronic illnesses is reflected in the company's most recent funding round.
We focus exclusively on this industry and provide insights that help you make better decisions. Get in touch to learn more@ https://www.precedenceresearch.com/stem-cell-therapy-market